Sanofi, Medtronic team up to offer options for diabetes patients

The new partnership focuses on innovative drug-device breakthroughs. 

By Nicole Gray • June 17, 2014

Medtronic buying Ireland-based Covidien

The merger will make Medtronic a mega-medical-device company.

By Nicole Gray • June 16, 2014

NICE reverses stance on skin cancer treatment after reviewing new survival data

The panel changed its decision of four months ago based on positive survival data extending out three years.

By Nicole Gray • June 16, 2014

Parion, Santen bring dry eye drug to Asian markets

The drug has a novel mode of action and will help Parion build an Asian distribution network with a new partner.

By Nicole Gray • June 13, 2014

X-Chem, Pfizer team up on orphan drug development

The collaboration pairs two companies that are powerful in different ways.

By Nicole Gray • June 13, 2014

Lilly's Cyramza fails in phase III liver cancer trials, but sees a way forward

Although the drug failed to show statistical results for survival advantage in patients with advanced liver cancer, there were some meaningful results.

By Nicole Gray • June 13, 2014

AstraZeneca breathes new life into its respiratory portfolio

The company has acquired rights to a drug developed by Synairgen and is reporting positive phase II results on its psoriatric arthritis drug.

By Nicole Gray • June 13, 2014

Valeant tries again and Allergan says 'no'

Same question, same answer. Allergan contends that Valeant's increased offer still undervalues the company. 

By Nicole Gray • June 11, 2014

Dendreon faces large debt payment as CEO departs

For the company, the combination of low Provenge sales and high debt has been challenging, leading to speculation about its future.

By Nicole Gray • June 11, 2014

GelStat gets medical marijuana foothold with Mastix Medica acquisition

The acquisition will bolster Gelstat's weight-loss chewing gum product line and allow the company to move into the high CBD/low THC market.

By Nicole Gray • June 10, 2014

South-Korea based Cho-A Pharma partners with Manchester United

Given the soccer team's fan base throughout Korea and Vietnam, this partnership represents a path to increase interest in Cho-A Pharm's nutritional and OTC products. 

By Nicole Gray • June 10, 2014

Merck bets big on hepatitis C market with Idenix purchase

The products being developed by the two firms are different types of drugs, with different mechanisms of action, but they all are oral and interferon-free.

By Nicole Gray • June 10, 2014

AstraZeneca ties its future to a promising drug pipeline

The firm predicts a nearly $20 billion increase in revenues by 2023, as it continues to develop small-molecule and biologics-based therapies for the treatment of various cancers.

By Nicole Gray • June 8, 2014

BMS and Indian CRO extend drug discovery contract

Eight years of collaboration between the two companies has produced six drug candidates. 

By Nicole Gray • June 5, 2014

Bayer, Orion partnering to develop prostate cancer drug

Bayer is trying to build a strong portfolio in this therapeutic area--and is off to a good start with Xofigo, which was approved last year. 

By Nicole Gray • June 5, 2014

Bayer CEO lays out departure plans

Even pharmaceutical executives grapple with work-life balance....Marijn Dekkers is planning to leave his chief executive officer position at Bayer by December 2016. 

By Nicole Gray • June 4, 2014

Valeant and Pershing Square initiate hostile takeover of Allergan

After increasing the offer by about 20%, the next move is to go straight to the shareholders.

By Nicole Gray • June 2, 2014

Hikma Pharmaceuticals to acquire Bedford

Two large acquisitions in less than four years has put UK-based Hikma on the map. Its latest acquisition may also include a manufacturing facility. 

By Nicole Gray • May 30, 2014

Pfizer expands OTC portfolio with launch of OTC Nexium 24HR

The launch marks the fourth therapeutic area in which the company has an OTC presence. Pfizer acquired rights to Nexium from AstraZeneca in 2012.

By Nicole Gray • May 29, 2014

BMS dives into the immunooncology fray with CytomX collaboration

Other companies, including Merck, AstraZeneca and Pfizer are also heavily involved in immunooncology. Data highlights from this research will be reported at ASCO.

By Nicole Gray • May 28, 2014

The Pfizer-AstraZeneca deal is a no-go

Very few observers had expected the Pfizer-AstraZeneca deal to move forward by the Monday deadline. AstraZeneca has confirmed its intention to remain independent, while Pfizer maintains that its offer was "compelling."

By Nicole Gray • May 27, 2014

Novartis will market Fovista for wet AMD outside of the U.S.

The company is partnering with Ophthotech Corp. in a deal worth $1 billion.

By Nicole Gray • May 21, 2014

AstraZeneca rejects latest Pfizer takeover bid

A hostile takeover attempt is not planned, Pfizer says.

By Nicole Gray • May 21, 2014

Valeant continues pursuit of Allergan, ponders company break-up

Although Allergan has rejected Valeant's latest $47 billion offer, CEO Michael Pearson continues to pursue the acquisition.

By Nicole Gray • May 21, 2014

Novartis to maintain Gleevec exclusivity until early 2016

The company has successfully defended its patent for Gleevec (imatanib mesylate) after months of litigation with Sun Pharma.

By Nicole Gray • May 20, 2014